Gastroenterology
Conference Coverage
ACS: No clear answers to black patients’ worse rectal cancer outcomes
Median survival was 109.6 months among white patients and 85.8 months among black patients with rectal cancer.
Conference Coverage
Transcription factor loss linked to worse colorectal cancer outcomes
In colorectal cancer arising in the hindgut, loss of SMAD4 is associated with worse recurrence-free survival.
Commentary
Commentary: Red meat and cancer risk – what your patients should know
The WHO’s classification of processed meat as a carcinogen and red meat as a probable carcinogen could help motivate patients to make healthier...
News
Adjuvant imatinib for 3 years better than 1 year in high-risk GIST
Key clinical point: Patients with high-risk GIST treated with adjuvant imatinib for 3 years had longer relapse-free survival (RFS) and overall...
News
No link found between immunosuppression and anal dysplasia in IBD
Immunosuppression did not affect the probability of abnormal anal cytology among patients with inflammatory bowel disease.
News
Low BMI predicted worse survival in mCRC
Key clinical point: Low BMI predicted worse overall and progression-free survival in patients with mCRC. Major finding: Risks of death and...
News
High-radiation doses improve survival with inoperable intrahepatic cholangiocarcinoma
Key clinical point: High-radiation doses delivered to hepatic tumors were well tolerated and survival outcomes were comparable to surgical...
News
DNA-based pancreatic cyst test guides treatment
A DNA-based molecular diagnostic test that stratifies pancreatic cysts for their malignant potential better than current alternatives can help...
News
FDA approves liposomal irinotecan for advanced pancreatic cancer
The Food and Drug Administration approved irinotecan liposome injection, in combination with fluorouracil and leucovorin, to treat patients with...
Community Translations
Dinutuximab combination therapy becomes first approval for high-risk neuroblastoma
Conference Coverage
Evidence builds for aspirin’s benefit in GI cancers
Postdiagnosis aspirin use nearly doubled survival in patients with gastrointestinal cancers in a large study from the Netherlands.